

Nimish Arun Mohile, MD, MS, FAAN
Associate Professor of Neurology and Cancer Center
University of Rochester Medical Center

Curriculum Vitae

CURRENT POSITIONS

The Ann Aresty Camhi Professor in Neurology
Associate Chair for Career Development and Leadership
Department of Neurology Diversity Officer
Director, Neuro-oncology Service Line
Division Chief, Neuro-oncology
Fellowship Program Director, Neuro-oncology
Vice Chair, AAN Section for Neuro-oncology

PERSONAL INFORMATION

Work Address: Wilmot Cancer Institute
University of Rochester Medical Center
601 Elmwood Avenue, Box 704
Rochester, NY 14642
Phone: 585-276-3972
Email: nimish_mohile@urmc.rochester.edu
Twitter: @nimishmohile

Home Address: 485 Clover Hills Drive
Rochester, NY 14618
Cell phone: 646-265-3037

Date of Birth: 05/26/1972
Place of Birth: Aberdare, Wales, United Kingdom
Citizenship: United States, naturalized 1985

EDUCATION

Undergraduate

1990- 1994 Duke University, Durham, NC
B.S. in Biology, 2nd major in French
Dean's List, 1994

Graduate

1995-1996 Georgetown University, Washington, DC
M.S. in Physiology with distinction

1996-2000 St. George's University School of Medicine, Grenada
M.D, Dean's List

2007-2013 University of Rochester, Rochester, NY
M.S in Translational Research

POSTDOCTORAL/RESIDENCY TRAINING

Intern
2001-2001 Yale-Norwalk Hospital, Norwalk, CT
Internal Medicine

Resident
2001-2004 Northwestern University, Chicago, IL
Neurology

Chief Resident
2003-2004 Northwestern University, Chicago, IL
Neurology

Fellow
2004-2005 Northwestern University, Chicago, IL
Neurophysiology

Fellow
2005-2007 Memorial Sloan-Kettering Cancer Center, NY, NY
Neuro-Oncology

ACADEMIC APPOINTMENTS

2007-2009 Senior Instructor of Neurology and Cancer Center
University of Rochester Medical Center

2009-2015 Assistant Professor of Neurology and Cancer Center
University of Rochester Medical Center

2015-present Associate Professor of Neurology and Cancer Center
University of Rochester Medical Center

PROFESSIONAL LICENSE

2005- 2020 New York State Medical License, #234343

BOARD CERTIFICATION

2005-present Diplomate, American Board of Psychiatry and Neurology

2009-present Certification in Neuro-Oncology, United Council of Neurologic Subspecialties

UNIVERSITY, PROFESSIONAL HOSPITAL AND ADMINISTRATIVE APPOINTMENTS

2007-present	Attending Physician Strong Memorial Hospital and Highland Hospital
2009- present	Division Chief of Neuro-oncology
2009- 2012	Assistant Program Director, Neuro-oncology Fellowship
2012-present	Program Director, Neuro-oncology Fellowship
2017-2020	Senator, University of Rochester Faculty Senate
2017- present	Department of Neurology Diversity Officer
2018- present	Associate Chair Career Development and Leadership, Department of Neurology
2019- present	Director, Neuro-oncology Service Line, Wilmot Cancer Center

MEMBERSHIP IN PROFESSIONAL SOCIETIES

Fellow, American Academy of Neurology 2018- present
 Member, American Academy of Neurology 2003- present
 Neuro-Oncology Section, 2007- present
 Member, American Society of Clinical Oncology, 2005- present
 Member, Society for Neuro-Oncology, 2005- present
 Member, American Association for Cancer Research 2019- present

INVITED PRESENTATIONS:

1. University of Rochester Medical Center, Department of Surgery Grand Rounds: **Re-inventing Faculty Development**. 9/17/20.
2. American Academy of Neurology Chair's Webinar: **Systemic Racism in Academic Departments**. 7/17/20, Presenter and Panelist
3. National Cancer Institute Webinar: **Navigating Brain and Spine Tumor Care through Telehealth**. 6/19/20, Organizer, Presenter and Panelist
4. 6th Congress of the European Academy of Neurology. **Disparities in Patient Enrollment on Glioblastoma Clinical Trials**. 5/25/20
5. American Academy of Neurology: Virtual Neuro-Oncology Section Meeting. **Considerations for Neuro-Oncologists During the COVID-19 Pandemic**. 5/3/2020
6. Wilmot Cancer Center Hematology-Oncology Division Seminar: **Creating an Academic Development Plan**, 12/12/20
7. Neuro-oncology Fellow Career Retreat at Society for Neuro-Oncology: **The Financial practice of Neuro-oncology**, 11/22/19.
8. Neuro-oncology Trainee Forum: **Building a Brain Tumor Program** 3/11/20.

9. University at Buffalo, Department of Neurology Grand Rounds: **The Clinical and Research Continuum in Glioblastoma**, 12/6/2018
10. Winship Cancer Center at Emory University, Research Seminar: **The Translational Research Continuum in Glioblastoma**, 09/25/2018
11. Transforming Leaders Program Presentation to American Academy of Neurology Board of Directors: **The Threat of Sub-specialization in Neurology**. 6/23/2018
12. University of Rochester Neurology Grand Rounds: **Identifying the Gaps in Glioblastoma**, 11/3/17
13. Cayuga Medical Center Grand Rounds: **Neuro-Oncologic Emergencies**, 10/23/2015
14. New England Neuro-Oncology Symposium: **A Palliative Care Intervention for Glioblastoma**. 09/27/2014
15. University of Rochester Medical Center Neurology Grand Rounds: **Neuro-Oncologic Emergencies**, 08/08/2014
16. University of Rochester, Wilmot Cancer Center Nursing Grand Rounds: **Primary CNS Lymphoma**, 06/26/2014
17. University of Rochester, Wilmot Cancer Center Grand Rounds: **Progress in Malignant Gliomas**, 02/08/2013
18. University of Rochester Medical Center Neurology Grand Rounds: **Update in Neuro-Oncology**, 08/10/2012
19. Unity Medical Center Medicine Grand Rounds: **Novel Strategies for the treatment of Glioblastoma**, 03/08/2011
20. Adult Glial Tumors; Discussion Chair; Patient Program: **Update in Neuro-Oncology: A Multidisciplinary Approach**; URM Department of Neurosurgery; Casa Larga Vineyards; Fairport, NY, 05/02/2008
21. Pediatric and Non-Glial Tumors: **Primary CNS Lymphoma**; Professional Program: Update in Neuro-Oncology: A Multidisciplinary Approach; URM Department of Neurosurgery; Casa Larga Vineyards; Fairport, NY, 05/02/2008
22. Pediatric and Non-Glial Tumors: **Primary CNS Lymphoma**; Patient Program: Update in Neuro-Oncology: A Multidisciplinary Approach; URM Department of Neurosurgery; Casa Larga Vineyards; Fairport, NY, 05/02/2008
23. **"Neurological Presentation of Systemic T-Cell Lymphoma in Immunocompetent Children"**; Lymphoma Blitz Poster Session; AAN, April 2005
24. **"Paraneoplastic cerebellar degeneration; Immunology and Pathogenesis"**; Department of Neurology Grand Rounds, Northwestern University, June 2004

PROFESSIONAL DEVELOPMENT

AAN Resident Annual Meeting Scholarship, AAN, 2004

AAN Palatucci Advocacy Leadership Forum, 2005

J. Kiffin Penry Epilepsy Mini-Fellowship Winston-Salem, NC, 2005

Memorial Sloan-Kettering Cancer Center Clinical Research Methodology Curriculum 2005 - 2007

Rochester Clinical Research Curriculum University of Rochester 2007 - 2012

Introduction to Medical Center Leadership Series University of Rochester 2008 - 2009

AACR, Molecular Biology in Clinical Oncology Workshop. Aspen, Colorado 2008

American Neurologic Association Course for Clinical and Translational Researchers at Vail 2009

NINDS, Clinical Trial Methods Course in Neurology Vail, Colorado. 2008

American Neurological Association Junior Academic Scholarship Award, 2009

AACR: Anti-cancer Agent Validation Workshop, Bethesda, Maryland, 2011

Improving Your Leadership Skills, A Practical Approach, AAN, 2015

Patient and Family Centered Care Coaching Program, University of Rochester, 2016

University of Rochester Mentors' Program, 2016

Transforming Leaders Program, AAN, 2017-2018

C-Change Leadership Program, Brandeis University, 2017-2018

Career Engagement, Revitalization, and Transition- A curriculum for Mid-Late Career Academic Faculty, URMC, 2018

AD HOC REVIEWER

Neurology

JAMA Neurology

Experimental Neurology

Leukemia Research

Journal of Geriatric Oncology

Cancer

Neuro-oncology

Journal of Neuro-oncology

Neurology Clinical Practice

CLINICAL ACTIVITIES

I created and established the Division of Neuro-Oncology at URMC in 2007, a program that has tripled in growth and now sees more than 100 brain tumor patients each year in addition to providing inpatient and outpatient neurologic consultative services to patients with cancer. I have fostered the development of niche clinics within neuro-oncology, including neurofibromatosis, tumor-related epilepsy CNS metastases, geriatric neuro-oncology and a cancer and cognition clinic. This is now one of the largest neuro-oncology divisions in the country with 5 primary neuro-oncology faculty, adjunct faculty in palliative care, epilepsy and oncology and 2 APPs. Since 2019, I direct the multi-disciplinary neuro-oncology service line and am responsible for coordinating and streamlining outpatient and inpatient services across five departments, growing a clinical trials program, developing business plans for new faculty recruits in addition to marketing, philanthropy and regional outreach.

1. Outpatient clinic (2 days/ week) in the multi-disciplinary neuro-oncology clinic at the Wilmot Cancer Center. This involves coordination of treatment of patients with primary brain tumors and consultative care in patients with metastatic brain tumors and neurologic complications of cancer.
2. Inpatient neuro-oncology consultations (12 weeks/ year)
3. Attending on Neurology consultation service at Strong Memorial Hospital (4 weeks/ year)
4. Participation in multidisciplinary brain tumor conference to aid in decision making for complex patients with primary and metastatic brain tumors. (weekly)

CLINICAL COMMITTEES

Department of Neurology Quality Management Committee, Northwestern University, 2003-2004
 Department of Neurology Chief's Committee, University of Rochester, 2009-present
 Neuro-Oncology Executive Committee, Service Line, 2007- present
 Lymphoma Service Line, 2015- present
 Wilmot Cancer Center Service Line Committee, 2018-present

NATIONAL CLINICAL COMMITTEES

AAN Neuro-oncology Quality Measure Working Group, 2017-2018

INTERNATIONAL CLINICAL COMMITTEES

ASCO Multi-site Guidelines Advisory Group, 2018-present
 ASCO Brain Metastases Guidelines Panel, 2019-present
 ASCO Glioma Guidelines Panel, Chair, 2019-present

EDUCATIONAL PORTFOLIO

I instituted and currently direct a variety of neuro-oncology education related activities at the University of Rochester. I established a 4th year medical student elective rotation, a neurology resident rotation, a neurology resident didactic curriculum and the UCNS accredited neuro-oncology fellowship. I have since trained 5 fellows who are all neuro-oncologist in Western NY. I also established a neurology resident mentoring and leadership program in 2017 and currently direct this. I participate annually in the Neurology localization series and Neurologic emergency series for incoming PGY2 neurology residents. I participate actively in resident recruitment, presenting the department's initiatives in mentoring and diversity as well as interviewing candidates.

National Education Activities**AAN Residency Examination Advisory Panel**

Clinical Adult Section Leader, 2012-2016
 Member, 2008-2016

AAN Annual Meeting Education Program

Neuro-Oncologic Emergencies, Speaker 2015
Neuro-Oncologic Emergencies, Course Director and Speaker 2016
Neuro-Oncologic Emergencies, Course Director and Speaker 2017

Core Principles of Brain Tumors, Course Director and Speaker, 2019
 Translational and Clinical Advances in Neuro-oncology, Scientific Session Moderator, 2019
Creating a Roadmap for a Diverse Workforce in Academic Neurology, Course Director 2019
 Head Talks: AAN Leadership: using Experiences to Answer the Tough Questions, 2019
 Neuro-oncology Guided Poster Walk, Lead and Discussant, 2019

Events cancelled due to COVID-19:

Core Principles of Brain tumors, Course Director and Speaker, 2020
Creating a Roadmap for a Diverse Workforce in Academic Neurology, Course Director 2020
 Experiential Learning Area Talk: *Are You Woke Enough to Lead*, 2020

AAN A.B. Baker Section of Neurologic Educators

A.B Baker Teacher Recognition Award, 2015
 Member, 2015- present

AAN Neuro-Oncology Topic Work Group, 2018-present
AAN Education Committee, 2019- present
AAN Resident Leadership Subcommittee, 2019- present

United Council of Neurologic Subspecialties

UCNS Certification Committee, 2016- present
 UCNS Neuro-Oncology Fellowship Milestones Committee, 2017-2020
 UCNS Neuro-Oncology Program Requirements Task Force, 2019- present

Institutional

Update in Neuro-Oncology CME planning committee, 2008-2009
 Hematology Oncology Fellow Lectures in neuro-oncology (4 lectures/ year), 2007- present
 Neuropsychiatry Lecture series for psychiatry residents (1 lecture/ year), 2015- present
 Physical Medicine and Rehab Annual Research Day Moderator, June 22nd,2017
 Center for Excellence in Teaching and Learning Webinar: “How Amazing Mentors Think About Mentoring”, 3/15/18

Departmental **Neurology**

Department of Neurology Faculty Teaching Award, University of Rochester, 2011
 Attend and Teach Neurology Residents and Medical Students on Professor Rounds (2 times/year).
 Director of Lumbar Puncture Clinic: Precept neurology residents, medical residents and medical students in performing lumbar punctures (weekly).
 Department of Neurology Fellowship Oversight Committee, 2014 - Present
 Educational Incentives Task Force Chair, 2015-2016
 Director, Neurology Resident Mentoring Program, 2017- present:
 Neurology Residency Program Evaluation Committee, 2017-present
 Director, Resident and Fellow Research Curriculum, 2020- present

Neuro-Oncology

UCNS Fellowship Program Director, 2011- present
 Director of Neuro-Oncology Fellowship Curriculum, a weekly lecture series.
 Director of Multi-Disciplinary Neuro-Oncology, a 4th year medical student elective, 2014-2019
 Neurology Residency Education Curriculum, a lecture series on neuro-oncology topics for neurology residents and medical students (8-12 lectures/year).
 Neuro-Oncology Elective Rotation: Director of outpatient and inpatient neuro-oncology elective for Neurology Residents, (4-6 residents/ year), 2014-2019

MENTORING TABLE

Mentee	Time Period	Project/ type of mentoring	Outcome	Current position
Undergraduate and Medical Students				
Shivani Patel (MS3)	2010-2011	CNS metastases in Esophageal Cancer	AAN Abstract	Medical Resident, UT Southwestern
Kathryn Somers (MS4)	2011-2012	Primary CNS Melanoma	Case report published in JCO	Dermatology Faculty, URM

Lauren Patrick (MS3)	2015-2016	PCNSL Review	Published in Current Oncology Reports	Neurology Resident at UCSF
Lauryn Hemminger (MS3)	2015-present	Palliative Care in Glioblastoma	Multiple Abstracts and publications Office of Medical Education Year out Research Award	Neurology Resident at URM
Jessica Occhiogrosso (Undergraduate)	2016-2018	Decision making in Glioblastoma	Senior Thesis Abstract with Oral Presentation at the AAN and Publication in J Pall Med	Senior Undergraduate Student, UR
Varun Mehta (MS3)	2019-present	Steroid-induced Metabolic Syndrome in Glioblastoma		
Jessena Maxwell (pre-doc program)	2018-present	Medical specialty preferences in under-represented minority undergraduate students		
Matt Randall (Undergraduate)	2019-present	Survey of Clinical Trial Preferences in Gliomas	American Academy of Neurology Undergraduate Research Scholarship	
Jared Macher (MS1)	2020-present	Feasibility of a steroid toxicity intervention in brain tumor patients	UR School of Medicine Summer Research Grant	
Residents and Fellows				
Ajay Abad, MD	2013-2015	VTE in Glioblastoma	ASCO Abstract	Assistant Professor, Neuro-Oncology, Roswell Park Cancer Institute
Andrea Wasilewski, MD	2014-present	Hospitalization in Glioblastoma Epilepsy education in brain tumors Bevacizumab in Pilocytic	Platform presentation and publication in Neuro-Oncology Practice Clinical Feasibility study and publication Abstract and	Assistant Professor, Neurology, URM

		Astrocytomas	publication in CNS oncology	
Chinazom Ibegbu, MD	2016-2018	Pregnancy in Brain Tumors	Textbook Chapter	Assistant Professor, Neuro-Oncology Roswell Park Cancer Institute
Sara Hardy, MD	2017-present	Predicting radiation induced cognitive dysfunction in brain tumor patients Advance Care Planning in Glioblastoma	CTSI Pilot Award Wilmot Cancer Research Fellowship Cancer Control Pilot Grant	Assistant Professor, Neurology and Radiation Oncology, URM
Manidhar Lekkala, MD	2019-present	Therapeutics for NSCLC Brain Metastases	Clinical Therapeutic Protocol	Hematology Oncology Fellow, URM
Graduate Students/Junior Faculty				
Megan Herr, PHD	2013-2016	Antidepressant use and CNS Metastases/ Epidemiology PHD Dissertation Committee	2 publications	Epidemiology Faculty, NCI
Jennifer Gewandter, PHD	2015-present	Intervention in CIPN	Clinical Feasibility study, multiple abstracts and publications R21 funded grant	Assistant Professor, Anesthesiology, URM
Ian Kleckner, PHD	2016-present	Interoceptive circuitry in CIPN	- Multiple abstracts - prospective clinical study - K07 awardee	Assistant Professor, Department of Surgery and Neuroscience, URM
Thomas Wychowski, MD	2012-present	Tumor related epilepsy in Glioblastoma	Multiple abstracts, publications and clinical protocols ECRIP grant NeuroNext Fellowship	Associate Professor, Neurology at URM
Andrew Bui	2016-present	Overutilization of MRI in Glioblastoma	IRB approved retrospective	Clinical Research Coordinator

		Master's Thesis Committee	protocol	
Robert Stone, MD	2018-present	Developing pipeline programs for under-represented minorities: pre-doc program	Inclusive Climate Fellowship	Associate Professor, Department of Neurology
Tirisham Gyang, MD	2019-2020	Career Mentoring, Diversity Leadership Program AAN		Assistant Professor, Neurology, University of Florida
Andrea Wasilewski, MD	2019-present	Geriatric Neuro-Oncology	Multiple abstracts and publications	Assistant Professor, Neuro-oncology, URMC
Ajay Dhakal, MD	2019-present	Clinical trials for CNS Metastases in Breast Cancer	Society for Neuro-oncology Clinical Trials Course Investigator-initiated Clinical Trial	Assistant Professor of Hematology-Oncology, URMC
Frank Akwaa, MD	2020-present	A Phase II Study of Avatrombopag for Temozolomide-induced Thrombocytopenia in Glioma	Investigator-initiated Clinical Trial	Assistant Professor of Hematology-Oncology, URMC

LEADERSHIP DEVELOPMENT AND ACTIVITIES

AAN Transforming Leaders Program: 2017-2018

A highly competitive 1-year leadership development program with a mentored individual leadership project, group project and exposure to leadership roles in the American Academy of Neurology.

C-Change Mentoring and Leadership Institute, Brandeis University: 2018

A selective 1-year program focused on individual academic development for leaders in academic medicine.

AAN Neuro-Oncology Section Leadership Group, 2018-Present

I work with others to strengthen the presence of neuro-oncology within the AAN and develop strategies to better engage our section members. In 2020, I became vice chair of the AAN Neuro-oncology section.

Advanced Leadership Training: Preparing for your career's insurmountable opportunities.

Speaker and Discussion Group Leader
AAN Annual Meeting, 2018, Los Angeles, CA

AAN Resident Leadership Subcommittee: 2019- present

Committee member and mentor for 2 residents

University of Rochester Philanthropy Champions: 2019-2020

A year-long series for University of Rochester leaders to develop skills to engage the community and donors in philanthropic efforts for clinical and research programs.

FACULTY AND PROFESSIONAL DEVELOPMENT ACTIVITIESAssociate Chair, Career Development and Leadership, 2018 to present:

In this role, I coordinate faculty development activities for over 30 junior faculty, career development for APPs and leadership development for residents, faculty, APPs and administrative staff. I work with departmental members to update and strengthen CV's, create an academic development plan, identify mentors, sponsor them for national mentorship and leadership activities, develop long term goals and short-term action plans. I work with the Department Chair to ensure that the departmental promotions process is transparent and equitable and I work with faculty to understand the promotions process, identify components and to develop and strengthen their promotion packets. I assist the department chair in coordinating the annual review process for all faculty and I serve as a liaison between faculty and their division chiefs in this process.

I created and direct the following year-long programs to help departmental members thrive in their positions:

Launch your Academic Career with Purpose: (2018- present, annual) A 1-year curriculum to identify and prioritize your values, create your personal vision and mission, develop short and long term goals and create a structured academic development plan.

Leadership Circle: (2019-2020) Faculty identify a leadership project within the department that aligns with the department's strategic plan and are assigned a faculty leadership mentor as well as a senior member of the administrative staff. Faculty are given key leadership articles that are discussed in a journal club format and discussions focus on putting participants own leadership projects and challenges into context of each article. Each faculty member creates an action plan for their project and presents their work at the end of the year.

Building Resilient Teams: (Initiated 2020) Faculty, trainees, staff and APPs work together on teams to plan and implement group leadership projects. The yearlong program helps individuals with leadership skills, emotional intelligence, strategies to improve teamwork and in building individual, team and organizational resilience.

APP Development: (Initiated 2020) Chart your own course- a 1-year curriculum for Neurology Advanced Practice Providers to help them develop leadership skills, identify short-term and long-term professional goals and create a structured career development plan.

Chief's leadership program: (Initiated 2020) Chief Residents identify a group leadership project and work through the year on leadership skills, teamwork, communication and emotional intelligence. They develop a structured action plan to implement their project.

Resident and fellow research curriculum: (2018- present, annual) A monthly structured 1-year program for residents and fellows new to research that goes through the step by step process of their first research project.

CONTRIBUTIONS TO DIVERSITY, EQUITY AND INCLUSIONDepartment of Neurology Diversity Officer, 2017 to present:

In this role, I attend monthly Medical Center meetings and lead several working groups to increase diversity in the department of Neurology, advocate for gender pay equity, develop faculty mentoring

and leadership programs, create pipeline programs for students under-represented in medicine, increase awareness of diversity issues in the department and create and implement an anti-racist action plan.

Special Commission on Racism, Inequity and Social Justice

Invited Member, June 2020-August 2020

A group of AAN leaders charged with developing recommendations for the Board of Directors to transform the AAN into a multicultural, antiracist organization.

AAN Diversity Officer's Working Group:

Co-Chair, 2019- present

Member, 2018-2019

This is a senior level working group charged with creating a cadre of diversity officers throughout academic neurology departments and identifying resource needs.

AAN Equity, Diversity, Inclusion and Disparities Joint Coordinating Council:

Member, 2019- present

A senior level coordinating committee that seeks to oversee all diversity related issues throughout the American Academy of Neurology

AAN Diversity Leadership Program:

Mentor, 2019

AAN Annual Meeting Education Program:

Creating a Roadmap for a Diverse Workforce in Academic Neurology, Course Director 2019

Creating a Roadmap for a Diverse Workforce in Academic Neurology, Course Director 2020

Experiential Learning Area Talk: *Are You Woke Enough to Lead*, 2020

University of Rochester Medical Center Diversity Working Group:

Member, 2018-present

A workgroup of departmental diversity officers at URMCC.

Pre-Doc Program, University of Rochester Medical Center:

Mentor for undergraduate students: 2018- present

RESEARCH PORTFOLIO

I established the brain tumor clinical trials program at the University of Rochester where I have served as Principal Investigator for over 20 NIH- sponsored, cancer consortium, foundation and industry clinical trials. The program accrues approximately 10- 20% of primary brain tumor patients onto experimental therapies and 50% onto observational studies. I chair the Wilmot Cancer Institute Neuro-Oncology Disease Working Group and am responsible for coordinating our clinical trial portfolio, prioritizing trials and ensuring appropriate scientific review of all neurology related clinical studies in our cancer center. I also work to develop and support multi-disciplinary supportive care studies for neuro-oncology patients for chemotherapy induced peripheral neuropathy, geriatric oncology, cognitive impairment and palliative care.

FELLOWSHIP AND RESEARCH AWARDS:

American Society of Clinical Oncology Foundation Merit Award | American Society of Clinical Oncology Foundation | 2007

Wilmot Cancer Research Fellowship University of Rochester "Gene Expression in sorted human glioma

progenitor cells." The purpose of this study is to identify and validate upregulated pathways in glioma progenitor cells as potential drug targets in the treatment of malignant gliomas. Mentor: Steven Goldman, MD PHD. | July 2008 - June 2011

Conquer Cancer Foundation (formerly ASCO Cancer Foundation) Career Development Award "Efficacy of Memantine in the Treatment of Recurrent Glioblastoma" The purpose of this study is to determine the safety and efficacy of Memantine in the treatment of recurrent Glioblastoma and to better understand the role of glutamate in the biology and progression of these tumors. Mentor: Steven Goldman, MD PHD | July 2010 - June 2013

SWOG Travel Award Recipient | Southwest Oncology Group | October 2011

RESEARCH COMMITTEES AND COLLABORATIONS

Data and Safety Monitoring Committee, Wilmot Cancer Center, University of Rochester 2007- present

SWOG- NCI cancer research consortium; Lymphoma Committee, 2010-2012

NRG Oncology- Brain Tumor Committee

International Primary CNS Lymphoma Collaborative Group

National Cancer Institute Primary Brain Lymphoma Working Group, 2010- 2012

AAN and SNO Neuro-Oncology Quality Measurement Work Group July 2016 – Present

UR Neuro Next Steering Committee 2016- present

FDA Orphan Products Development Clinical Trials Grant Review Panel 2017 and 2019

NCI Working Group in Primary CNS Lymphoma, 2019- present

American Brain Foundation Expert Review Panel

NINDS T32 Training Grant: Experimental Therapeutics- Executive Committee 2019-present

National Brain Tumor Society Research Roundtable- July 2020

RESEARCH PRESENTATIONS

Master's Thesis Proposal University of Rochester Master's in Clinical and Translational Research, Project: Tissue Biomarkers of Tumor Associated Epilepsy, Mentorship Committee: Robert Block MD, Robert Holloway MD, Mahlon Johnson MD, Chis Beck, PHD. | July 2011 - July 2012

Working Group for Clinical Trials, University of Rochester Medical Center: Development of a Novel Drug Combination for Glioblastoma, 01/15/2016

Working Group for Clinical Trials, University of Rochester Medical Center: Wearable TENs Band for Chronic CIPN: Results of a Single-Arm Feasibility Study and Implications for the Design of an Early Phase Randomized Trial, 2/10/2017

CTSI Research Methods Forum, University of Rochester Medical Center: A phase I study of a triplet therapy in glioblastoma. 12/19/17.

RESEARCH GRANTS (NIH Sponsored)

Wireless transcutaneous electrical stimulation (TENS) for chemotherapy-induced peripheral neuropathy: a phase II randomized clinical trial.

Role: Medical monitor, Co-investigator

Sponsor: National Institutes of Health, R21 CA235389

2019- present

Phase 2 Study of Cytochrome C Oxidase Activity as a Biomarker in Subjects with Newly Diagnosed Primary Glioblastoma Multiforme.

Role: Site PI

Sponsor: NeuroNext Consortium

2016- present

CALGB-51101: A Randomized Phase II Trial of Myeloablative versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-Cell Lymphoma

Role: SWOG Principal Investigator and Site PI

Sponsor: Alliance

2013- present

RESEARCH GRANTS (Foundation Sponsored)

RTOG 3503 Phase II Trial of Optune plus Bevacizumab in Bevacizumab-refractory recurrent glioblastoma.

Role: Site PI

Sponsor: RTOG Foundation

2017-present

Gene Expression in Sorted Human Glioblastoma Progenitor Cells

Role: Principal Investigator

Sponsor: Wilmot Cancer Research Foundation

2008-2011

Efficacy of Memantine in the Treatment of Recurrent Glioblastoma

Role: Principal Investigator

Sponsor: Conquer Cancer Foundation

2010-2013

RESEARCH GRANTS (Industry Sponsored)

Safety and Activity of Brivaracetam in the Prevention of Tumor-Related Epilepsy in Patients with High Grade Gliomas.

Role: PI, Investigator-initiated study

Sponsor: UCB Pharma

A Randomized, Multicenter, Phase II Study of DSP-78888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy

Role: Site PI

Sponsor: Boston Biomedical

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma.

Role: Site PI

Sponsor: Tocagen

2015-present

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy

Role: Site PI

Sponsor: Boston Biomedical
2018-present

Phase 2 Dose-Escalation Study of TPI-287 in Combination with Bevacizumab in Adults with Recurrent or Progressive Glioblastoma Following Bevacizumab Alone.

Role: Site PI

Sponsor: Cortice Biosciences
2014-present

Phase 1 Dose-escalation study of TPI-287 in Combination with Bevacizumab Followed by Randomized Study of the Maximum Tolerated Dose of TPI 287 in Recurrent Glioblastoma.

Role: Site PI

Sponsor: Cortice Biosciences
2014-present

A Feasibility study of a TENS unit for the treatment of Chemotherapy Induced Peripheral Neuropathy.

Role: PI

Sponsor: Quell
2016- present

Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined with Bevacizumab vs. Bevacizumab Monotherapy in Patients with Recurrent Glioblastoma.

Role: Site PI

Sponsor: Vascular Biogenics
2015- present

Phase 3 Randomized Double-Blind, Controlled Study of ICT-107 with Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant Chemoradiotherapy.

Role: Site PI

Sponsor: Immunocellular Therapeutics
2015-present

A maintenance study evaluating the long term safety of XL184 in subjects with advanced malignancies previously enrolled in other XL184 studies

Role: Site PI

Sponsor: Exilixis
2011- 2014

Phase 1 Dose-Escalation Study of XL765 in Combination with Temozolomide in Subjects with Malignant Gliomas.

Role: Site PI

Sponsor: Sanofi-Aventis
2010-2013

Phase 2 Non-comparative Randomized Open Label Study of Multi Regimens of Single Agent XL184 in Subjects with Grade IV Astrocytic Tumors in First or Second Relapse.

Role: Site PI

Sponsor: Exilixis
2010-2014

Randomized, double-blind study of rindopepimut/GM-CSF with adjuvant temozolomide in subjects with newly diagnosed EGFRvIII-positive glioblastoma

Role: Site PI
Sponsor: Celldex
2012-2015

Cilengitide in subjects with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter a multicenter, open-label phase 2 study investigating two cilengitide regimens in combination with standard treatment

Role: Site PI
Sponsor: Merck
2010-2012

Cilengitide in subjects with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter a multicenter, open-label, controlled phase III study testing cilengitide in combination with standard treatment versus standard treatment alone.

Role: Site PI
Sponsor: Merck
2009-2012

INVESTIGATIONAL NEW DRUG APPLICATIONS:

Dr. Mohile holds IND # 138073 titled, **A Phase 1 Trial of Maprotiline in Combination with Temozolomide and Tamoxifen in the Treatment of Recurrent Glioblastoma** with the FDA to conduct this study.

PEER REVIEWED PUBLICATIONS (Mentees underlined)

1. **Mohile NA**, Spector AR, Ebong IM, Flippen C, Gutierrez C, Leacock RO, Marulanda-Londoño E, Mejia NI, Thomas R, Hamilton RH. Developing the neurology diversity officer: A roadmap for academic neurology departments. *Accepted to Neurology, In Press*
2. Warren KT, Liu L, Liu Y, Strawderman MS, Hussain AH, MA HM, Milano MT, **Mohile NA**, Walter KA. Time to treatment initiation and outcomes in high-grade glioma patients in rehabilitation; a retrospective cohort study. *CNS Oncol.* 2020 Oct 28
3. Liu Y, Strawderman MS, Warren KT, Richardson M, Serventi JN, **Mohile NA**, Milano MT, Walter KA. Clinical Efficacy of Tumor Treating Fields for Newly Diagnosed Glioblastoma. *Anticancer Res.* 2020 OCT; 40 (10):5801-5806
4. Lukas R, Taylor JW, Kurz SC and **Mohile NA**. *Clinical neuro-oncology for the neurologist.* *Neurol Clin Pract.* October 2020, 10(5) 458-465
5. Wychowski T, Fessler JA, Nadler J, **Mohile N** et al. A feasibility study of electrocorticography during routine craniotomy to predict tumor-related epilepsy. *Interdisciplinary Neurosurgery.* September 2020

6. Wasilewski A, Alam A and **Mohile N**. Chemotherapy toxicities and geriatric syndromes in older patients with malignant gliomas. *J Geriatr Oncol* Jul 2020 PMID: 32674977
7. Liu Y, Wasilewski A, **Mohile NA**. Disparities in patient enrollment on glioblastoma clinical trials. *CNS Oncol*. June 2020 PMID: 32603616
8. Wasilewski A, **Mohile N**. Meet the expert: How I treat chemotherapy-induced peripheral neuropathy. *J. Geriatr Oncol*, June 2020 PMID: 32561202
9. Cloughesy TF, Brenner A, de Groot JF and GLOBE Study Investigators. A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE) *Neuro Oncol*. 2020 May 15;22(5):705-717.
10. **Mohile NA**, Blakely JO, Gatson NN et al. *Urgent considerations for the neuro-oncologic treatment of patients with gliomas during the COVID-19 pandemic*. *Neuro-oncology* April 2020
11. Liu X, Tian W, Kolar B, Johnson MD, Milano M, Jiang H, Lin S, Li D, **Mohile NA**, Li YM, Walter KA, Ekholm S, Wang H. *The correlation of fractional anisotropy parameters with Ki-67 index and the clinical implication in grading of non-enhancing gliomas and neuronal-gial tumors*. *Magn Reson Imaging* 2019 Oct 20
12. Kluger BM, Ney DE, Bagley SJ, **Mohile N**, Taylor LP, Walbert T, Jones CA. *Top Ten Tips Palliative Care Clinicians Should Know When Caring for Patients with Brain Cancer*. *J Palliat Med* 2019 Oct 15
13. Occhiogrosso J, Hemminger L, Burke J, Ibegbu C, Serventi J, **Mohile N**. *Treatment-Related Decisions in Malignant Gliomas: A Feasibility Study*. *J Palliat Med*. 2019 Jul 30 2019
14. Wasilewski A, Serventi J, Ibegbu C, Wychowski t, Burke J, **Mohile N**. *Epilepsy Education in gliomas: engaging patients and caregivers to improve care*. *Support Care Cancer*. Jul 2 2019
15. Gewandter JS, Chaudari J, Ibegbu C, Kitt R, Serventi J, Burke J, Culakova E, Kolb N, Sluka KA, Tejani MA, **Mohile NA**. *Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open label feasibility study*. *Support Care Cancer*. May 2019
16. **Mohile, NA**. *Glioblastoma in 140 Characters*. *Neurology* 2018 Apr 24;90 (17)803-4
17. Wasilewski A and **Mohile N**. *Durable response to bevacizumab in adults with recurrent pilocytic astrocytoma*. *CNS Oncol*. 2018 Apr 9.
18. Jordan JT, Sanders AE, Armstrong T, Asher T, Bennett A, Dunbar E, **Mohile N**, Nghiemphu PL, Smith TR, Ney DE. *Quality improvement in neurology: Neuro-Oncology Quality Measurement Set*. *Neurology* 2018 Apr 3; 90(14) 652-8
19. **Mohile NA**. *Medical Complications of Brain Tumors*. *Continuum*. 2017 Dec; 23 (6, Neuro-oncology) PMID: 29200115
20. Kleckner, I. R., Kamen, C., Gewandter, J. S., **Mohile, NA.**, Heckler, C.E., Culakova, E., Fung, C., Janelsins, M.C., Asare, M., Lin, P., Reddy, P.S., Giguere, J., Berenberg, J., Kesler, S.R., Mustian, K.M. *Effects of Exercise during Chemotherapy on Chemotherapy-Induced Peripheral Neuropathy: A Multicenter, Randomized Controlled Trial*. *Supportive Care in Cancer*. 2017

21. Chinnaiyan P, Won M, Wen PY, Rojiani AM, Werner-Wasik M, Shih HA, Ashby LS, Yu HM, Stieber VW, Malone SC, Fiveash JB, **Mohile NA**, Ahluwalia MS, Wendland MM, Stella PJ, Kee AY, Mehta MP. *A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: Results of NRG Oncology RTOG 0913*. *Neuro-Oncol*. 2017; PMID: 29126203
22. Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH; **ACT IV trial investigators**. *Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial*. *Lancet Oncol*, 2017; PMID: 28844499
23. Gewandter JS, Freeman R, Kitt RA, Cavaletti G, Gauthier LR, McDermott MP, **Mohile NA**, Mohile SG, Smith AG, Tejani MA, Turk DC, Dworkin RH. *Chemotherapy-induced peripheral neuropathy clinical trials: Review and recommendations*. *Neurology* 2017. PMID: 28747442
24. Thomas AA, Abrey LE, Terziev R, Raizer J, Martinez NL, Forsyth P, Paleologos N, Matasar M, Sauter CS, Moskowitz C, Nimer SD, DeAngelis LM, Kaley T, Grimm S, Louis DN, Cairncross JG, Panageas KS, Briggs S, Faivre G, **Mohile NA**, Mehta J, Jonsson P, Chakravarty D, Gao J, Schultz N, Brennan CW, Huse JT, Omuro A. *Multicenter Phase II Study of Temozolomide and Myeloablative Chemotherapy with Autologous Stem Cell Transplant for Newly Diagnosed Anaplastic Oligodendroglioma*. *Neuro Oncol*. 2017 PMID: 2847259
25. Wasilewski A, Serventi J, Kamalyan L, Wychowski T, **Mohile N**. *Acute Care in Glioblastoma: The Burden and the Consequences*. *Neurooncol Pract*. 2017
26. Connelly J, Hormigo A, **Mohile N**, Hu J, Chaudhry A, Blondin N. *Planning TTFields treatment using the NovoTAL system-clinical case scenarios beyond the use of MRI contrast enhancement*. *BMC Cancer*. 2016; 16:842
27. Trusheim J; Dunbar E; Battiste J; Iwamoto F; **Mohile N**; Damek D; Bota DA; Connelly J. *A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma*. *CNS oncology*. 2016; PMID: 27628854
28. Herr MM; **Mohile NA**; Barr PM; van Wijngaarden E; Brown EB; Rich DQ. *Survival of Secondary Central Nervous System Lymphoma Patients in the Rituximab Era*. *Clinical lymphoma, myeloma & leukemia*. 2016; PMID: 27375157
29. Herr MM; **Mohile NA**; van Wijngaarden E; Brown EB; Rich DQ. *Antidepressant use and risk of central nervous system metastasis*. *Journal of neuro-oncology*. 2016; PMID: 27289477
30. Gewandter JS; Dworkin RH; Finnerup NB; **Mohile NA**. *Painful chemotherapy-induced peripheral neuropathy: lack of treatment efficacy or the wrong clinical trial methodology?* *Pain*. 2016; Epub 2016 Jun 27.
31. Bashir R; **Mohile NA**. *Solving the riddle of glioblastoma: The hope for immunotherapy*. *Neurology*. 2016;86(24):2220-1.
32. Robins HI; Zhang P; Gilbert MR; Chakravarti A; de Groot JF; Grimm SA; Wang F; Lieberman FS; Krauze A; Trotti AM; **Mohile N**; Kee AY; Colman H; Cavaliere R; Kesari S; Chmura SJ; Mehta M. *A randomized phase I/II study of ABT-888 in combination with temozolomide in*

- recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study.* Journal of neuro-oncology. 2016;126(2):309-16.
33. **Mohile NA.** *How I treat glioblastoma in older patients.* Journal of geriatric oncology. 2016;7(1):1-6.
 34. Cummings M; Dougherty D; **Mohile N**; Walter K; Usuki K; Milano M. *Severe radiation-induced leukoencephalopathy: Case report and literature review.* Advances in Radiation Oncology. 2016; 1: 17-20.
 35. Hemming L; Pittman CA; Korones DN; Serventi JN; Ladwig S; Holloway RG; **Mohile NA.** *Palliative and end-of-life care in glioblastoma: defining and measuring opportunities to improve care.* Neuro-Oncology Practice. 2016; .
 36. Wen PY; Omuro A; Ahluwalia MS; Fathallah-Shaykh HM; **Mohile N**; Lager JJ; Laird AD; Tang J; Jiang J; Egile C; Cloughesy TF. *Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.* Neuro-oncology. 2015;17(9):1275-83.
 37. Patrick LB; **Mohile NA.** *Advances in Primary Central Nervous System Lymphoma.* Current oncology reports. 2015;17(12):60.
 38. Ray S; Bonafede MM; **Mohile NA.** *Treatment Patterns, Survival, and Healthcare Costs of Patients with Malignant Gliomas in a Large US Commercially Insured Population.* American health & drug benefits. 2014;7(3):140-9.
 39. Wychowski T; Wang H; Buniak L; Henry JC; **Mohile N.** *Considerations in prophylaxis for tumor-associated epilepsy: prevention of status epilepticus and tolerability of newer generation AEDs.* Clinical neurology and neurosurgery. 2013;115(11):2365-9.
 40. Somers KE; Almast J; Biemiller RA; Silberstein HJ; Johnson MD; **Mohile NA.** *Diagnosis of primary CNS melanoma with neuroimaging.* Journal of clinical oncology: 2013;31(1):e9-11.
 41. **Mohile NA**; Zoccoli CM; Glantz M. *Is brain the new bone marrow? Stem cells, cancer, and cognition: a working hypothesis.* Neurology. 2011;76(13):1118-20.
 42. Milano MT; Okunieff P; Donatello RS; **Mohile NA**; Sul J; Walter KA; Korones DN. *Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma.* International journal of radiation oncology, biology, physics. 2010;78(4):1147-55.
 43. Milano MT; Johnson MD; Sul J; **Mohile NA**; Korones DN; Okunieff P; Walter KA. *Primary spinal cord glioma: a Surveillance, Epidemiology, and End Results database study.* Journal of neuro-oncology. 2010;98(1):83-92.
 44. Gutin PH; Iwamoto FM; Beal K; **Mohile NA**; Karimi S; Hou BL; Lymberis S; Yamada Y; Chang J; Abrey LE. *Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.* International journal of radiation oncology, biology, physics. 2009;75(1):156-63.
 45. **Mohile NA**; Deangelis LM; Abrey LE. *Utility of brain FDG-PET in primary CNS lymphoma.*

Clinical advances in hematology & oncology : H&O. 2008;6(11):818-20, 840.

46. **Mohile NA**; Forsyth P; Stewart D; Raizer JJ; Paleologos N; Kewalramani T; Louis DN; Cairncross JG; Abrey LE. *A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis*. Journal of neuro-oncology. 2008;89(2):187-93.
47. **Mohile NA**; Deangelis LM; Abrey LE. *The utility of body FDG PET in staging primary central nervous system lymphoma*. Neuro-oncology. 2008;10(2):223-8.
48. **Mohile NA**; Abrey LE. *Primary central nervous system lymphoma*. Neurologic clinics. 2007;25(4):1193-207.
49. **Mohile NA**; Abrey LE. *Primary central nervous system lymphoma*. Seminars in radiation oncology. 2007;17(3):223-9.
50. Bassuk AG; **Mohile NA**; Stack C. *T-cell lymphoma presenting with neurologic features in immunocompetent children*. Pediatric neurology. 2006;35(5):314-7.

ABSTRACTS

Yang Liu, Andrea Wasilewski and Nimish Mohile. Disparities in US Glioblastoma Clinical Trials. **Accepted for Oral Presentation: 6th Congress of European Academy of Neurology, May 25th, 2020**

Yang Liu, Andrea Wasilewski and Nimish Mohile. Underrepresentation of Women and Older Patients in US Glioblastoma Clinical Trials. **Accepted for Poster Presentation: American Academy of Neurology 2020** (meeting cancelled due to COVID-19)

Ahmar Alam, Andrea Wasilewski and Nimish Mohile. Geriatric Syndromes and Treatment Toxicities in Older Patients with Malignant Gliomas. **Accepted for Poster Presentation: American Academy of Neurology 2020** (meeting cancelled due to COVID-19)

Samantha Myers, Peggy Auinger, Gretchen Birbeck, Joy Burke, Chinazom Ibegbu, Nimish Mohile, Andrea Wasilewski, Jennifer Serventi, Thomas Wychowski. Scores and Performance of Patient Reported Outcome Measures in Patients with High Grade Glioma at Diagnosis. **Accepted for Poster Presentation: American Academy of Neurology 2020** (meeting cancelled due to COVID-19)

Raval B, Hemminger L, Hay A, Auinger P, Birbeck GL, Serventi J, Occhiogrosso J, Ibegbu C, Burke J, Mohile N, Wychowski T. Quality of Life Measures in Tumor-related Epilepsy in Adult Patients with High-Grade Gliomas. **Poster Presentation: American Epilepsy Society Annual Meeting. December 9, 2019.**

Ian Kleckner, Jennifer S. Gewandter, Charles E. Heckler, Susan Staples, Ann Colasurdo, Po-Ju Lin, Michelle Shayne, Alissa Huston, Allison Magnuson, Mohamedtaki Abdulaziz Tejani, Richard Francis Dunne, Chunkit Fung, Brea Lipe, Frank Charles Passero, Nimish Mohile, Gary R. Morrow, Michelle Christine Janelins, and Karen Michelle Mustian. The effect of structured exercise during chemotherapy on chemotherapy-induced peripheral neuropathy (CIPN): A role for interoceptive brain circuitry. Journal of Clinical Oncology 2019 37:15_suppl, 11590-11590

Poster Presentation: ASCO Annual Meeting 2019

Yang Liu, Margie Richardson, Kwanza Warren, Myla S. Strawderman, Nimish Mohile, Michael T. Milano, and Kevin Walter. Clinical efficacy of tumor-treating fields for newly diagnosed glioblastoma. *Journal of Clinical Oncology* 2019 37:15_suppl, 2046-2046

Poster Presentation: ASCO Annual Meeting 2019

Andrea Wasilewski, Jennifer Serventi, Chinazom Ibegbu, Joy Burke, Thomas Wychowski, Nimish Mohile. Feasibility of a Structured Tumor-related Epilepsy Education Intervention in Adult Gliomas *Neurology* Apr 2019, 92 (15 Supplement)

Poster Presentation and Guided Poster Walk Selection: AAN Annual Meeting 2019

Jessica Occhiogrosso, Lauryn Hemminger, Joy Burke, Chinazom Ibegbu, Jennifer Serventi Nimish Mohile. Treatment-Related Decisions in Malignant Gliomas: A Feasibility Study *Neurology* Apr 2019, 92 (15 Supplement)

Oral Platform Presentation: AAN Annual Meeting 2019

Wasilewski A, Serventi J, Ibegbu C, Burke J, Wychowski T, Mohile N. P01.008. Feasibility of a structured tumor related epilepsy education intervention in adult gliomas. *Neuro-Oncology*, Volume 20, Issue suppl_3, September 2018, Page iii229.

Poster Presentation European Association for Neuro-Oncology, Stockholm, October 2018.

Hemminger L, Serventi J, Korones D, Holloway R, Mohile N. Caregiver Burden in Glioblastoma. *Neuro-Oncology*, Volume 20, Issue suppl_3, September 2018,

Poster Presentation European Association for Neuro-Oncology, Stockholm, October 2018.

Wasilewski, Andrea, and Nimish Mohile. Durable response to bevacizumab in adults with recurrent pilocytic astrocytoma (P4. 163). (2018): P4-163.

Oral Platform Presentation: AAN Annual Meeting 2018

Kleckner IR; Aslin RN; Heckler CE; Janelins MC; Mohile NA; Asare M; Cole C; Lin P; Mustian KM; Rao V; Kesler SR. (2017) A longitudinal brain fMRI study of chemotherapy-induced peripheral neuropathy in 50 breast cancer patients. American Society for Clinical Oncology. Chicago, IL, USA.

Poster Presentation: ASCO Annual Meeting 2017

Goldlust, Samuel Aaron, Louis B. Nabors, Nimish Mohile, Tara L. Benkers, Sigmund H. Hsu, Sandra Silberman, Samuel Singer, Mayank Rao, Lori Cappello, and George Farmer. Final results from the dose-escalation stage of a phase 1/2 trial of TPI 287, a brain penetrable microtubule inhibitor, plus bevacizumab in patients with recurrent glioblastoma. (2017): 2021-2021.

Poster Presentation: ASCO Annual Meeting 2017

Kleckner IR; Aslin RN; Heckler CE; Janelins MC; Mohile NA; Asare M; Cole C; Lin P; Mustian KM; Rao V; Kesler SR. (2017) Chemotherapy-induced peripheral neuropathy is associated with altered connectivity in interoceptive brain circuitry.

Neuropathic Pain Special Interested Group Meeting from the International Association for the Study of Pain. Gothenburg, Sweden, 2017.

Hemminger LE, Pittman CA, Korones DN, Serventi JN, Holloway RG, Mohile NA. Early Palliative Care Consultation in Glioblastoma. (2017): P1-165.

Poster Presentation: AAN Annual Meeting 2017

George, Benjamin, Kylie George, Andrea Wasilewski, and Nimish Mohile. US Burden of Hospital Admissions and Utilization of Hospice Care for Patients with Malignant Brain Tumor (P4. 326). (2017): P4-326.

Poster Presentation: AAN Annual Meeting 2017

Kleckner IR; Aslin RN; Heckler CE; Janelins MC; Mohile NA; Asare M; Cole C; Lin P; Mustian KM; Rao V; Kesler SR. (2017) The role of the brain in chemotherapy-induced peripheral neuropathy: an fMRI study.

Poster Presentation MASCC Annual Meeting 2017

Hemminger LE, Pittman CA and Mohile NA. Caregiver Time Burden in Newly Diagnosed Glioblastoma: A prospective Analysis.

Poster Presentation ASCO Palliative Care Symposium 2016

Goldlust S, Nabors L, Duic P, Mohile, N, Benkers T, HSU, Silberman S, Singer S, Rao M, Farmer G. A Phase 1/2 Trial of Bevacizumab Plus TPI 287, A Brain Penetrable Anti-Microtubule Agent, in Patients with Recurrent Glioblastoma.

Poster Presentation ASCO Annual Meeting 2016

Chris L, Serventi J, Ladwig S, Korones D, Holloway R and Mohile N. Patterns of End of Life Care in a Retrospective Cohort of Glioblastoma Patients. (P4. 243)." (2016): P4-243.

Poster Presentation: AAN Annual Meeting 2016

Wasilewski A, Serventi J, Kamalyan L, Wychowski T and Mohile N. Acute Care Utilization in Glioblastoma (GBM): A descriptive analysis of causes, burden and outcomes. (S34. 008)." (2016): S34-008.

Platform Presentation: AAN Annual Meeting 2016

Silberman, Sandra L., Samuel Goldlust, L. Burt Nabors, J. Paul Duic, Tara Benkers, Nimish Mohile, Donald Picker, Samuel Singer, and George Farmer. Interim results from a phase I/II trial of TPI 287, a novel brain penetrable antimicrotubule agent, in combination with bevacizumab for the treatment of recurrent glioblastoma.In *CANCER RESEARCH*, vol. 75.

Poster Presentation AACR Annual Meeting 2015

Abad A, Serventi, J and Mohile NA. Application of a predictive model for development of VTE in systemic cancers for Glioblastoma. (2014): 2073-2073.

Poster Presentation ASCO Annual Meeting 2014

Wychowski T, Buniak L, Serventi J, Henry J and Mohile NA: Seizure Prophylaxis in Patients with De Novo Glioblastoma: Should AAN Guidelines Be Revisited? (2012): P04-185.

Poster Presentation AAN Annual Meeting 2012

Patel S, Serventi J and Mohile NA: A Retrospective study of CNS Metastases in Esophageal Carcinoma.

Poster Presentation AAN Annual Meeting 2010

Mohile NA and Abrey LE: Assessment of treatment response to Bevacizumab with MRI in recurrent malignant Glioma. *NEURO-ONCOLOGY*, vol. 9, no. 4, pp. 516-516

Poster Presentation SNO Annual Meeting 2007

Mohile NA, Abrey LE, Lymberis SC, Karimi S, Hou BL and Gutin PH. A Pilot Study of Bevacizumab and Stereotactic Intensity Modulated Re-irradiation for Recurrent High Grade Gliomas.

Poster Presentation, Poster Discussion and ASCO Foundation Merit Award: ASCO Annual Meeting 2007

Mohile NA, Lassman AB, Louis DN, Kewalramani T, Forsyth P, Stewart D, Paleologos N, Raizer J, DeAngelis LM, Cairncross JG and Abrey LE: High dose chemotherapy with autologous stem cell rescue (ASCR) for newly diagnosed anaplastic oligodendroglial tumors: Preliminary report of the Oligodendroglioma Study Group.

Poster Presentation SNO Annual Meeting 2006

Mohile NA, DeAngelis LM, Abrey LE: The role of systemic and cranial 18fluorodeoxyglucose positron emission tomography (FDG PET) in primary central nervous system lymphoma (PCNSL).

J Clin Oncol 24:66s, 2006.

Poster Presentation ASCO Annual Meeting 2019

Bassuk A, Mohile NA and Stack C. Neurological presentation of systemic T-cell Lymphoma in Immunocompetent Children.

Poster presentation and oral blitz session at AAN Annual Meeting 2005.

TEXTBOOK CHAPTERS

Abrey LE and Mohile NA. "Principles of Chemotherapy". Brain Tumors: Practical Guide to Diagnosis and Treatment. Baehring J, Pipemeier J. New York: Informa Health Care, USA, 2007.

Mohile, N.A.; Raizer, J.J. "Chemotherapy of Neuronal Tumors". Handbook of Brain Tumor Chemotherapy. Newton, H.B. Amsterdam: Boston: Elsevier, 2006.

Shaikh, N, Mohile, NA and Raizer JJ. "Chemotherapy for glioneuronal tumors". Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics and Immunotherapy. Newton, H.B. London: Elsevier 2018

Ibegbu, I and Mohile NA. "Brain Tumors in Pregnancy", Neurological Diseases and Pregnancy. Ciafaloni E, Thornburg L and Bushnell C. New York: Oxford University Press 2018

COMMUNITY ENGAGEMENT

Annual National Brain Tumor Foundation Caregiver Event: Rochester, NY Role: Physician Sponsor and Speaker, Title of Presentation: Uncertainty in the Management of Brain Tumors | May 2010

Annual National Brain Tumor Foundation Caregiver Event: Rochester, NY Role: Physician Sponsor and Speaker, Title of Presentation: Uncertainty in the Management of Brain Tumors | May 2011

American Brain Tumor Association Running Team for the Chicago Marathon Raised \$8,500 | October 2011

Biomarkers in the era of personalized medicine University of Rochester Brain Tumor Support Program | 11/19/2012

Pluta Breast Cancer Support Group: Chemotherapy Induced Peripheral Neuropathy | February 2014

Annual National Brain Tumor Foundation Caregiver Event: Rochester, NY Role: Physician Sponsor and

Speaker, Title of Presentation: Uncertainty in the Management of Brain Tumors | May 2013

Gilda's Club Myeloma Support Group: Managing Symptoms for Chemotherapy Induced Neuropathy | 04/22/2014

Physician Advisor, Adding Candles, a local philanthropic organization dedicated to raising money for brain tumor research, 2015 – present. This now supports an annual peer-reviewed \$50,000 grant for brain tumor research.

MEDIA INTERVIEWS

Electric Brain Field Device Slows Deadly Tumors

NBC News with Lester Holt

December 15th, 2015

<https://www.nbcnews.com/health/cancer/electric-brain-field-device-slows-deadly-tumors-n480436>

Mother in remission grateful for Wilmot Clinical Trial

WHAM news, Jennifer Johnson

Tuesday January 19th, 2016

<http://13wham.com/news/top-stories/mother-in-remission-grateful-for-wilmot-clinical-trial>

McCain cancer diagnosis: URMC working on easier way to treat Glioblastoma

WHAM news

July 20th, 2017

<http://13wham.com/news/local/mccain-cancer-diagnosis-urmc-working-on-easier-way-to-treat-glioblastoma>

Glioblastoma: What it is and how it impacts patients.

WROC with Emily Noonan

July 20th, 2017

<http://www.rochesterfirst.com/news/local-news/glioblastoma-what-it-is-and-how-it-impacts-patients/770420852>

Breakthrough skull cap beats back Clay man's scary cancer

CNY

December 22, 2017

<http://cnycentral.com/news/local/breakthrough-skull-cap-beats-back-clay-mans-scary-cancer>

Professionalism: Neurologist or Specialist, Where do you fit in?

Orly Avitzur, Neurology Today, September 20, 2018

https://journals.lww.com/neurotodayonline/Fulltext/2018/09200/Professionalism_Neurologist_or_Specialist_Where.10.aspx